Clinical Trials on Hilar Cholangiocarcinoma in Austria

Total 30 results

Austin Health

Unknown

Study of RAD001 in Advanced Cholangiocarcinoma: RADiChol (RADiChol)

Cholangiocarcinoma

Australia
Sirtex Medical

Completed

SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma (SIRCCA)

Intrahepatic Cholangiocarcinoma

France, United Kingdom, Belgium, Australia, Spain, United States, Italy, Netherlands
Incyte Corporation

Recruiting

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma (FIGHT-302)

Metastatic Cholangiocarcinoma | Unresectable Cholangiocarcinoma

United States, Canada, Belgium, France, Germany, Italy, China, Spain, Japan, United Kingdom, Netherlands, Switzerland, Austria, Denmark, Finland, Ireland, Israel, Norway, Sweden
QED Therapeutics, Inc.
Helsinn Healthcare SA

Terminated

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

FGFR2 Gene Mutation | Advanced Cholangiocarcinoma

Korea, Republic of, United States, Belgium, Spain, Taiwan, China, United Kingdom, France, Canada, Germany, Thailand, Italy, Portugal, Australia, Puerto Rico
Taiho Oncology, Inc.

Recruiting

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement (FOENIX-CCA4)

Advanced Cholangiocarcinoma | FGFR2 Fusions | Gene Rearrangement

United States, Korea, Republic of, Spain, Japan, Portugal, Italy, China, Argentina, Brazil, Poland, Australia
University Hospital Plymouth NHS Trust
University of Plymouth

Completed

Recurrence After Whipple's (RAW) Study

Pancreatic Cancer | Surgery | Bile Duct Cancer | Pancreatic Ductal Adenocarcinoma | Survivorship | Cholangiocarcinoma, Extrahepatic | Cancer Recurrence | Recurrent Cancer | Pancreatic Ductal Carcinoma | Cholangiocarcinoma of the Extrahepatic Bile Duct | Ampullary Cancer | Cholangiocarcinoma Resectable | Cancer... and other conditions

Spain, United Kingdom, Australia, Austria, Italy, Mexico, Sudan, Pakistan
Taiho Oncology, Inc.

Active, not recruiting

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements (FOENIX-CCA3)

Advanced Cholangiocarcinoma | FGFR2 Gene Rearrangements

United States, Spain, United Kingdom, Australia, Taiwan, Italy, France, Korea, Republic of, Belgium, Japan, Thailand, Germany, Brazil, Peru, Portugal, Argentina, Hong Kong, Mexico, Netherlands, Poland
Servier Affaires Médicales

Recruiting

An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma (ProvIDHe)

Cholangiocarcinoma

France, Netherlands, Spain, Belgium, Sweden, Italy, Australia, Austria, Germany, United Kingdom
PrECOG, LLC.
Celgene Corporation

Completed

Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma (PrE0204)

Cholangiocarcinoma

United States, Austria
Medical University of Graz

Unknown

Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care

Quality of Life | Breast Cancer | Lung Cancer | Cholangiocarcinoma | Advanced Cancer | Pancreas Cancer | Colo-rectal Cancer | Symptoms and Signs

Austria
Forma Therapeutics, Inc.

Completed

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme) | Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas) | Cohort 3a and 3b: Chondrosarcoma | Cohort 4a and 4b: Intrahepatic... and other conditions

United States, Korea, Republic of, Australia, United Kingdom, Spain, France
Pfizer

Terminated

Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer

Advanced Breast Cancer (Parts 1 and 2) | Advanced Pancreatic Cancer (Part 1) | Advanced Colorectal Cancer (Part 1) | Advanced Cholangiocarcinoma (Part 1) | Advanced Glioblastoma Multiforme (Part 1)

United States, Spain, Hong Kong, Belgium, Australia, France
Relay Therapeutics, Inc.

Active, not recruiting

REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | FGFR2 Gene Mutation | FGFR2 Amplification | FGFR2 Gene Fusion/Rearrangement | FGFR2 Gene Translocation | FGFR2 Gene Activation | Other Solid Tumors, Adult

United States, France, Italy, United Kingdom, Korea, Republic of, Spain, Taiwan, Sweden, Germany, Netherlands, Singapore, Australia, Hong Kong
TransThera Sciences (Nanjing), Inc.

Recruiting

Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma (FIRST-308)

Cholangiocarcinoma

Korea, Republic of, United States, Spain, Taiwan, France, Belgium, Germany, Italy, Portugal, United Kingdom, Austria, Poland
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study of ICP-192 in Patients With Advanced Solid Tumors

Advanced Solid Tumors | Cholangiocarcinoma | Urothelial Carcinoma

Australia, United States
Wellmarker Bio
Covance

Recruiting

A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors

Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Lung Cancer | Cholangiocarcinoma | Advanced Solid Tumor | Metastatic Solid Tumor

Korea, Republic of, Australia
Arbele Pty Ltd

Recruiting

Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients

Gastric Cancer | Pancreatic Cancer | Cholangiocarcinoma | Esophageal Adenocarcinoma | Gastrointestinal Cancer | Liver Cancer | Colorectal Adenocarcinoma | Gastroesophageal Junction

Hong Kong, Australia
Universitätsklinikum Hamburg-Eppendorf
Cancer Research UK; Deutsche Krebshilfe e.V., Bonn (Germany); Australasian Gastro-Intestinal... and other collaborators

Active, not recruiting

Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer (ACTICCA-1)

Cholangiocarcinoma | Gall Bladder Carcinoma

Germany, Netherlands, United Kingdom, Australia, Denmark, Italy, New Zealand, Austria
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC

Cholangiocarcinoma | Biliary Tract Cancer | Gallbladder Cancer

Korea, Republic of, United States, Taiwan, China, Argentina, Australia, Brazil, Chile, France, Germany, Italy, Japan, Poland, Spain, United Kingdom
Taiho Oncology, Inc.

Completed

A Study of TAS-120 in Patients With Advanced Solid Tumors

Breast Cancer | Gastric Cancer | Cholangiocarcinoma | Urothelial Cancer | Primary CNS Tumors | Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors

France, United States, Korea, Republic of, United Kingdom, Japan, Hong Kong, Australia, Taiwan, Italy, Canada, Germany, Netherlands, Spain
Eli Lilly and Company
Loxo Oncology, Inc.

Active, not recruiting

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Glioma | Cholangiocarcinoma | Chondrosarcoma | Any Solid Tumor

United States, Spain, Korea, Republic of, Australia, Japan, Taiwan, France, Singapore, Hong Kong
Compass Therapeutics

Recruiting

A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)

Cholangiocarcinoma | Biliary Tract Cancer | Gall Bladder Cancer | Ampullary Cancer

United States
Quadriga Biosciences, Inc.
Novotech (Australia) Pty Limited

Completed

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

Melanoma | Sarcoma | Kidney Cancer | Cervical Cancer | Breast Cancer | Head and Neck Cancer | Astrocytoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Thymic Carcinoma | Lung Cancer | Prostate Cancer | Brain Cancer | Cholangiocarcinoma | Bladder Cancer | Liver Cancer | Brain Metastases | Tongue Cancer | Esophagus... and other conditions

Australia
NGM Biopharmaceuticals, Inc
Merck Sharp & Dohme LLC

Recruiting

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Non-small Cell Lung Cancer | Colorectal Carcinoma | Bladder Urothelial Cancer | Endocervical...

United States
Telix International Pty Ltd

Recruiting

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Soft Tissue Sarcoma | Cervical Cancer | Nasopharyngeal Carcinoma | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Glioblastoma Multiforme | Non Small Cell Lung Cancer | Cholangiocarcinoma | Epithelial Ovarian Cancer | Head and Neck Squamous Cell Carcinoma and other conditions

United States
Elevation Oncology

Active, not recruiting

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Sarcoma | Kidney Cancer | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Cholangiocarcinoma | Bile Duct Cancer | Bladder Cancer | Metastatic Solid Tumor | Gallbladder Cancer | Uterine Cancer | Locally Advanced Solid Tumor

United States, Korea, Republic of, Australia, Canada
MacroGenics

Completed

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Cervical Cancer | Hematologic Neoplasms | Ovarian Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Small-cell Lung Cancer | TNBC - Triple-Negative Breast Cancer | HER2-positive Advanced Solid Tumors

Hong Kong, United States, Thailand, Australia, Spain, Bulgaria, Poland, Ukraine
Hoffmann-La Roche

Terminated

A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors (ALpha-T)

Digestive System Diseases | Gastrointestinal Diseases | Melanoma | Sarcoma | Neoplasms | Respiratory Tract Diseases | Neoplasms by Site | Gastrointestinal Neoplasms | Digestive System Neoplasms | Head and Neck Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms and other conditions

United States
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Cervical Cancer | Small Cell Lung Carcinoma | Neuroendocrine Tumor | Advanced Solid Tumors | Mesothelioma | Vulvar Cancer | Cholangiocarcinoma | Bile Duct Cancer | Endometrial Cancer | Advanced Cancer | Cervical Carcinoma | Endometrial Carcinoma | Thyroid Carcinoma | Thyroid Cancer | Anal Cancer | Colorectal Carcinoma | Carcinoid... and other conditions

Canada, France, Germany, Italy, Mexico, Netherlands, Poland, Russian Federation, Taiwan, United States, Brazil, Colombia, Israel, Korea, Republic of, Norway, Philippines, South Africa, Spain, Australia, Denmark, Chile, Portugal, Peru
Hoffmann-La Roche

Active, not recruiting

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)

Melanoma | Renal Cell Carcinoma | Adult Solid Tumor | Breast Cancer | Head and Neck Neoplasms | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Neuroendocrine Tumors | Lymphoma, Large-Cell, Anaplastic | Cholangiocarcinoma | Papillary Thyroid Cancer | Sarcomas | Salivary Gland Cancers and other conditions

United States, China, Korea, Republic of, Australia, Taiwan, France, Spain, United Kingdom, Hong Kong, Belgium, Italy, Germany, Japan, Singapore, Netherlands, Poland

Clinical Trials on Hilar Cholangiocarcinoma in Austria

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations